PDBsum entry 4mz2

Membrane protein

PDB id: 4mz2

Contents

Protein chain

111 a.a.

Waters ×131

PDB id:

4mz2

Name:

Membrane protein

Title:

Crystal structure of the voltage-gated sodium channel beta 4 subunit extracellular domain

Structure:

Sodium channel subunit beta-4. Chain: a. Fragment: unp residues 32-157. Engineered: yes

Source:

Homo sapiens. Human. Organism_taxid: 9606. Gene: scn4b. Expressed in: escherichia coli. Expression_system_taxid: 562

Resolution:

1.72Å R-factor: 0.190 R-free: 0.228

Authors:

S.Das,F.Van Petegem

Key ref:

J.Gilchrist et al. (2013). Crystallographic insights into sodium-channel modulation by the β4 subunit. Proc Natl Acad Sci U S A, 110, E5016. PubMed id: 24297919 DOI: 10.1073/pnas.1314557110

Date:

28-Sep-13 Release date: 04-Dec-13

Protein chain

Q8IWT1  (SCN4B_HUMAN) -  Sodium channel subunit beta-4 from Homo sapiens

Seq: 228 a.a.

Struc: 111 a.a.*

* PDB and UniProt seqs differ at 1 residue position (black cross)

DOI no: 10.1073/pnas.1314557110

Proc Natl Acad Sci U S A 110:E5016 (2013)

PubMed id: 24297919

Crystallographic insights into sodium-channel modulation by the β4 subunit.

J.Gilchrist, S.Das, F.Van Petegem, F.Bosmans.

ABSTRACT

Voltage-gated sodium (Nav) channels are embedded in a multicomponent membrane signaling complex that plays a crucial role in cellular excitability. Although the mechanism remains unclear, β-subunits modify Nav channel function and cause debilitating disorders when mutated. While investigating whether β-subunits also influence ligand interactions, we found that β4 dramatically alters toxin binding to Nav1.2. To explore these observations further, we solved the crystal structure of the extracellular β4 domain and identified (58)Cys as an exposed residue that, when mutated, eliminates the influence of β4 on toxin pharmacology. Moreover, our results suggest the presence of a docking site that is maintained by a cysteine bridge buried within the hydrophobic core of β4. Disrupting this bridge by introducing a β1 mutation implicated in epilepsy repositions the (58)Cys-containing loop and disrupts β4 modulation of Nav1.2. Overall, the principles emerging from this work (i) help explain tissue-dependent variations in Nav channel pharmacology; (ii) enable the mechanistic interpretation of β-subunit-related disorders; and (iii) provide insights in designing molecules capable of correcting aberrant β-subunit behavior.